Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06113016 · ClinicalTrials.gov registry record · Phase 2
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
A Phase 2 study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 6
- Study locations
NCT06113016 is a Phase 2 study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8 that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 164 participants, below the 303-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (46% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT06113016, a Phase 2 study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Exercise Intervention
- OTHER Educational Intervention
- DRUG Fisetin
- OTHER Physical Performance Testing
Study Locations (6)
California
- UCLA Health Cancer Care in Alhambra - Alhambra
- UCLA Health Beverly Hills Primary & Specialty Care - Beverly Hills
- UCLA Health Burbank Primary & Specialty Care - Burbank
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- UCLA Health Primary Care in Marina del Rey - Marina del Rey
- UCLA Health Primary Care in Pasadena - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06113016
The ClinicalTrials.gov registry entry for NCT06113016 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 303-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (46% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06113016 reports 6 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06113016 about?
NCT06113016 is a clinical study titled "Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors". This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have unde...
What is the current status of trial NCT06113016?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2024-07-23. Estimated completion is 2028-12-30.
What conditions does trial NCT06113016 study?
This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8.
What interventions are being tested in trial NCT06113016?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Exercise Intervention (OTHER), Educational Intervention (OTHER), Fisetin (DRUG), Physical Performance Testing (OTHER).
Who is sponsoring clinical trial NCT06113016?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06113016 being conducted?
This trial has 6 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anatomic Stage III Breast Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
RECRUITING · Phase 2
-
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
RECRUITING · Phase 2
-
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
RECRUITING · Phase 2
Explore more on PlainTrial
Anatomic Stage III Breast Cancer AJCC v8
All registered trials for this condition
Anatomic Stage II Breast Cancer AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.